Please assess the completion status of the following clinical trial:

Trial Title: RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 3 to 70 years.~2. Diagnosis of r/r T-ALL/NK-ALL, T-LBL, or T-NHL (including PTCL-NOS, AITL, ALCL, Extranodal NK/T cell lymphoma).~3. ECOG: 0-2.~4. Life expectancy greater than 12 weeks.~5. Cardiac left ventricle ejection fraction ≥50%.~6. Informed consent explained to, understood by and signed by the patient/guardian. Patient/guardian is given a copy of informed consent.~Exclusion Criteria:~1. Pregnant or lactating.~2. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection is not within the normal range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C Viral (HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA positive; syphilis positive.~3. Patients with graft-versus-host disease (GVHD) or who need to use immunosuppressive drugs.~4. Participated in other clinical studies within 2 weeks prior to screening.~5. History of alcoholism, drug abuse or mental illness.~6. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- RD13-01 cell infusion (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).